Encapsulation of lipophilic ingredients in dispensible spray dried powders suitable for inhalation
AssigneeFlurry Powders, LLC
InventorsAndrew John Boeckl, David Edward Cookson
Life of this patent
Estimating the term…
Abstract
A method of manufacturing a flowable and dispersible powder includes solubilizing a lipophilic substance in a terpene to form a mixture and treating the mixture to form a nanoemulsion dispersed in an aqueous solution. The aqueous solution includes at least one functional excipient. The nanoemulsion is then spray dried, thereby evaporating first the aqueous portion and then the terpene to form a dry powder formed from solid particles comprising the lipophilic substance.
Claims21
A method of manufacturing a flowable and dispersible powder, the method comprising:
- solubilizing a lipophilic substance and a phospholipid in a terpene to form a lipophilic mixture;
- adding at least one functional excipient to water to form an aqueous solution in which the functional excipient is dissolved;
- after the at least one functional excipient is completely dissolved, dispersing the lipophilic mixture into the aqueous solution using one or both of a homogenizer or an ultrasonic device to form a coarse emulsion;
- treating the coarse emulsion with a microfluidizer to form a nanoemulsion;
- and
- spray drying the nanoemulsion to evaporate at least a portion of the terpene and substantially all of the water to form a dry powder for pulmonary administration in powder form, the dry powder being formed from solid particles comprising the lipophilic substance, the resultant dry powder having a mass median aerosol diameter (MMAD) between 0.5 and 5 μm, and a fine particle fraction (FPF) and delivery efficiency (DE) greater than 60%.
A method of manufacturing a flowable and dispersible powder, the method comprising:
- solubilizing a lipophilic substance and a phospholipid in a terpene to form a lipophilic mixture;
- adding at least one functional excipient to water to form an aqueous solution in which the functional excipient is dissolved;
- after the at least one functional excipient is completely dissolved, dispersing the lipophilic mixture into the aqueous solution using one or both of a homogenizer or an ultrasonic device to form a coarse emulsion;
- treating the coarse emulsion with one or both of the ultrasonic device or a high shear device to form a nanoemulsion;
- and
- spray drying the nanoemulsion to evaporate at least a portion of the terpene and substantially all of the water to form a dry powder for pulmonary administration in powder form, the dry powder being formed from solid particles comprising the lipophilic substance, the resultant dry powder having a mass median aerosol diameter (MMAD) between 0.5 and 5 μm, and a fine particle fraction (FPF) and delivery efficiency (DE) greater than 60%.
Dependencies are inferred from the claim text.